FAAH
Basic information
Region (hg38): 1:46394317-46413848
Links
Phenotypes
GenCC
Source:
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the FAAH gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 9 | |||||
missense | 24 | 29 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 1 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 4 | 4 | ||||
non coding | 1 | |||||
Total | 0 | 1 | 24 | 7 | 8 |
Variants in FAAH
This is a list of pathogenic ClinVar variants found in the FAAH region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
1-46394398-C-T | not specified | Uncertain significance (Dec 19, 2022) | ||
1-46394427-G-C | not specified | Uncertain significance (Apr 25, 2023) | ||
1-46394428-T-C | not specified | Uncertain significance (Oct 20, 2023) | ||
1-46394442-T-G | not specified | Uncertain significance (Nov 08, 2021) | ||
1-46394451-C-G | not specified | Uncertain significance (Sep 13, 2023) | ||
1-46394454-A-C | not specified | Uncertain significance (Sep 17, 2021) | ||
1-46402113-C-T | not specified | Uncertain significance (May 24, 2024) | ||
1-46402178-GC-G | FAAH-related disorder | Uncertain significance (Apr 08, 2024) | ||
1-46402200-G-C | not specified | Uncertain significance (May 12, 2024) | ||
1-46405032-G-A | not specified | Uncertain significance (Jan 26, 2023) | ||
1-46405033-G-A | Benign (Jul 18, 2018) | |||
1-46405089-C-A | FAAH POLYMORPHISM • Polysubstance abuse, susceptibility to • FAAH-related disorder | Benign/Likely benign (Oct 08, 2021) | ||
1-46405097-G-C | not specified | Uncertain significance (Oct 17, 2023) | ||
1-46405396-A-C | not specified | Uncertain significance (Jun 07, 2023) | ||
1-46405416-G-A | FAAH-related disorder | Likely benign (Jun 03, 2019) | ||
1-46405418-C-T | not specified | Uncertain significance (May 05, 2023) | ||
1-46405426-G-A | not specified | Uncertain significance (Dec 16, 2023) | ||
1-46405474-G-A | not specified | Uncertain significance (Jun 07, 2023) | ||
1-46405475-TG-T | Polysubstance abuse, susceptibility to | Likely pathogenic (Mar 29, 2024) | ||
1-46405631-T-C | not specified | Uncertain significance (Apr 13, 2022) | ||
1-46405665-G-C | not specified | Uncertain significance (May 26, 2024) | ||
1-46405702-C-G | Benign (Dec 31, 2019) | |||
1-46406041-G-A | Benign (Mar 30, 2018) | |||
1-46406072-G-C | not specified | Uncertain significance (Apr 11, 2023) | ||
1-46406255-G-T | not specified | Uncertain significance (Mar 01, 2023) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
FAAH | protein_coding | protein_coding | ENST00000243167 | 15 | 19584 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
4.44e-11 | 0.557 | 125656 | 0 | 92 | 125748 | 0.000366 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 0.638 | 276 | 307 | 0.898 | 0.0000182 | 3670 |
Missense in Polyphen | 110 | 128.47 | 0.85623 | 1532 | ||
Synonymous | -0.362 | 139 | 134 | 1.04 | 0.00000834 | 1216 |
Loss of Function | 1.34 | 20 | 27.6 | 0.725 | 0.00000130 | 331 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000335 | 0.000335 |
Ashkenazi Jewish | 0.000298 | 0.000298 |
East Asian | 0.000489 | 0.000489 |
Finnish | 0.00171 | 0.00171 |
European (Non-Finnish) | 0.000230 | 0.000229 |
Middle Eastern | 0.000489 | 0.000489 |
South Asian | 0.000329 | 0.000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Degrades bioactive fatty acid amides like oleamide, the endogenous cannabinoid, anandamide and myristic amide to their corresponding acids, thereby serving to terminate the signaling functions of these molecules. Hydrolyzes polyunsaturated substrate anandamide preferentially as compared to monounsaturated substrates. {ECO:0000269|PubMed:17015445}.;
- Pathway
- Retrograde endocannabinoid signaling - Homo sapiens (human);Cannabinoid receptor signaling;Gastric ulcer formation;metabolism of anandamide an endogenous cannabinoid;Metabolism of lipids;anandamide degradation;Arachidonic acid metabolism;Metabolism;Fatty acid metabolism
(Consensus)
Recessive Scores
- pRec
- 0.162
Intolerance Scores
- loftool
- 0.812
- rvis_EVS
- -0.47
- rvis_percentile_EVS
- 23.43
Haploinsufficiency Scores
- pHI
- 0.112
- hipred
- N
- hipred_score
- 0.387
- ghis
- 0.553
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.754
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Faah
- Phenotype
- integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); homeostasis/metabolism phenotype; muscle phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); normal phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);
Gene ontology
- Biological process
- fatty acid catabolic process;arachidonic acid metabolic process
- Cellular component
- endoplasmic reticulum membrane;cytoskeleton;integral component of membrane;organelle membrane
- Molecular function
- amidase activity;protein binding;fatty acid amide hydrolase activity;acylglycerol lipase activity;oleamide hydrolase activity;anandamide amidohydrolase activity